Summary
750.57
4.57
(0.61%)
04/17/2026
Regeneron Pharmaceuticals, Inc. (REGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 0.61 | -0.38 | -1.44 | 1.89 | 31.39 | 36.56 | 49.43 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | A |
| Recommended Rating | Buy |
| DCF | Strong Buy |
| ROE | Buy |
| ROA | Strong Buy |
| Debt/Equity | Sell |
| P/E | Neutral |
| P/B | Neutral |
Earnings
| Trading Data | ||
| Close | 750.57 | |
| Open | 754.74 | |
| High | 758.61 | |
| Low | 746.91 | |
| Volume | 512,335 | |
| Change | 4.57 | |
| Change % | 0.61 | |
| Avg Volume (20 Days) | 646,860 | |
| Volume/Avg Volume (20 Days) Ratio | 0.79 | |
| 52 Week Range | 474.61 - 820.12 | |
| Price vs 52 Week High | -8.48% | |
| Price vs 52 Week Low | 58.15% | |
| Range | -0.47 | |
| Gap Up/Down | -11.02 | |
Profitibility | ||
| Market Capitalization (Mln) | 68,166 | |
| Revenue per share | 139.3868 | |
| Net Income per share | 43.7794 | |
| Dividend Yield | 0.0048 | |
| Dividend Share | 358.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 17.1444 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
04/14 14:00 EST - zacks.com
Regeneron Boosts Cancer Pipeline Through Telix Collaboration
Regeneron teams up with Telix in a 50/50 radiopharma deal, betting on next-gen cancer therapies to expand its oncology pipeline and long-term growth.
Regeneron Boosts Cancer Pipeline Through Telix Collaboration
Regeneron teams up with Telix in a 50/50 radiopharma deal, betting on next-gen cancer therapies to expand its oncology pipeline and long-term growth.
04/13 10:46 EST - zacks.com
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.
04/13 09:56 EST - zacks.com
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
04/13 06:30 EST - globenewswire.com
Telix and Regeneron Announce Strategic Radiopharma Collaboration
MELBOURNE, Australia and INDIANAPOLIS and TARRYTOWN, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN, “Regeneron”) today announce a collaboration to jointly develop and commercialize...
Telix and Regeneron Announce Strategic Radiopharma Collaboration
MELBOURNE, Australia and INDIANAPOLIS and TARRYTOWN, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN, “Regeneron”) today announce a collaboration to jointly develop and commercialize...
04/13 06:30 EST - globenewswire.com
Regeneron and Telix Announce Strategic Radiopharma Collaboration
Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model
Regeneron and Telix Announce Strategic Radiopharma Collaboration
Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model
04/13 01:00 EST - globenewswire.com
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria activity compared with placebo in adults
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria activity compared with placebo in adults
04/13 01:00 EST - globenewswire.com
Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
04/09 12:40 EST - zacks.com
REGN or ILMN: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
REGN or ILMN: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Regeneron (REGN) or Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
04/09 04:57 EST - defenseworld.net
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cache Advisors LLC
Cache Advisors LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 43.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,548 shares of the biopharmaceutical company's stock after...
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cache Advisors LLC
Cache Advisors LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 43.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,548 shares of the biopharmaceutical company's stock after...
04/08 03:31 EST - defenseworld.net
Asio Capital LLC Makes New $3.42 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
Asio Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 4,434 shares of the biopharmaceutical company's stock,...
Asio Capital LLC Makes New $3.42 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
Asio Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 4,434 shares of the biopharmaceutical company's stock,...
04/08 02:15 EST - defenseworld.net
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of “Moderate Buy” from Analysts
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-seven analysts that are currently covering the stock, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold rating, sixteen have given a buy rating...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of “Moderate Buy” from Analysts
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-seven analysts that are currently covering the stock, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold rating, sixteen have given a buy rating...
04/06 16:11 EST - zacks.com
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
REGN wins FDA nod to extend Eylea HD dosing to 20 weeks, boosting flexibility for wAMD and DME patients while reinforcing its push to offset declining Eylea sales.
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
REGN wins FDA nod to extend Eylea HD dosing to 20 weeks, boosting flexibility for wAMD and DME patients while reinforcing its push to offset declining Eylea sales.
04/06 13:00 EST - zacks.com
All You Need to Know About Regeneron (REGN) Rating Upgrade to Buy
Regeneron (REGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About Regeneron (REGN) Rating Upgrade to Buy
Regeneron (REGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
04/05 06:22 EST - defenseworld.net
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC
Sovran Advisors LLC reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 22.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,619 shares of the biopharmaceutical company's stock after selling 2,519 shares during the...
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC
Sovran Advisors LLC reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 22.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,619 shares of the biopharmaceutical company's stock after selling 2,519 shares during the...
04/03 13:11 EST - zacks.com
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
04/03 11:47 EST - prnewswire.com
TriNetX arbeitet mit Regeneron zusammen, um Zugang zu anonymisierten elektronischen Patientenakten von 300 Millionen Patienten zu erhalten und damit die Forschung und Produktentwicklung in den Bereichen Biowissenschaften und digitale Gesundheitslösungen voranzutreiben
Regeneron hat die exklusive Möglichkeit, umfangreiche Genom- und Proteom-Datensätze mit dem branchenführenden globalen Netzwerk von TriNetX für elektronische
TriNetX arbeitet mit Regeneron zusammen, um Zugang zu anonymisierten elektronischen Patientenakten von 300 Millionen Patienten zu erhalten und damit die Forschung und Produktentwicklung in den Bereichen Biowissenschaften und digitale Gesundheitslösungen voranzutreiben
Regeneron hat die exklusive Möglichkeit, umfangreiche Genom- und Proteom-Datensätze mit dem branchenführenden globalen Netzwerk von TriNetX für elektronische
04/03 09:09 EST - prnewswire.com
TriNetX colabora con Regeneron para acceder a registros electrónicos de salud anonimizados
- TriNetX colabora con Regeneron para acceder a registros electrónicos de salud anonimizados de 300 millones de pacientes e impulsar la investigación y el
TriNetX colabora con Regeneron para acceder a registros electrónicos de salud anonimizados
- TriNetX colabora con Regeneron para acceder a registros electrónicos de salud anonimizados de 300 millones de pacientes e impulsar la investigación y el
04/03 03:09 EST - defenseworld.net
Aberdeen Group plc Has $124.84 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN
Aberdeen Group plc raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 6.8% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,738 shares of the...
Aberdeen Group plc Has $124.84 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN
Aberdeen Group plc raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 6.8% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,738 shares of the...
04/02 23:56 EST - prnewswire.com
TriNetX collabore avec Regeneron pour accéder aux dossiers médicaux électroniques dépersonnalisés de 300 millions de patients afin de stimuler la recherche et le développement de produits dans le domaine des sciences de la vie et des solutions de santé numérique
Regeneron a l'opportunité unique de connecter des cohortes de données génomiques et protéomiques à grande échelle au réseau mondial de données de dossiers
TriNetX collabore avec Regeneron pour accéder aux dossiers médicaux électroniques dépersonnalisés de 300 millions de patients afin de stimuler la recherche et le développement de produits dans le domaine des sciences de la vie et des solutions de santé numérique
Regeneron a l'opportunité unique de connecter des cohortes de données génomiques et protéomiques à grande échelle au réseau mondial de données de dossiers
04/02 16:30 EST - prnewswire.com
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continue to...
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continue to...
Market News
×
Loading news…